| News

docdok.health increases safety of coronavirus vaccinations

23.02.2021

The Basel-based start-up docdok.health has developed an app that aims to increase the safety and efficacy of COVID-19 vaccinations. The company has agreed a partnership with the German umbrella organization of specialized physicians (SpiFa).

As detailed in a press release, the Basel start-up docdok.health AG is the new innovation and technology partner of SpiFa (Spitzenverband Fachärzte Deutschland), the German umbrella organization of specialized physicians. SpiFa has recommended to its members – some 160,000 doctors – that they should use an app developed by docdok.health after COVID-19 vaccinations.

The app can be used to collect data which is then anonymously forwarded on to the Paul Ehrlich Institute, otherwise known as the Federal Institute for Vaccines and Biomedicines in Germany. A broad database should also allow processes to be optimized, which will result in improved safety and efficacy for COVID-19 vaccinations.

“We see huge potential for our app in Switzerland”, comments Yves Nordmann, co-founder and Chief Medical Officer (CMO) of docdok.health, in the press release. Founded in 2017, docdok.health AG develops solutions to improve communications between doctor and patient. “The focus is on healthcare provision that prioritizes quality over quantity with the help of digital therapy solutions”, explains co-founder and CEO Ulrich Mühlner, who was also formerly a Senior Manager at Novartis.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Bottmedical enters the market with innovative braces
Basel Area Business & Innovation, Innovation, Invest

Bottmedical enters the market with innovative braces

The Basel-based startup Bottmedical has developed clear braces made from bio-based polymers. After closing a successful financing round, the company...

Read More
TargImmune raises nearly 18 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

TargImmune raises nearly 18 million Swiss francs

The Basel-based biotechnology firm TargImmune has raised 17.7 million Swiss francs as part of a financing round. It now intends...

Read More
KetoSwiss launches first product in the USA
Basel Area Business & Innovation, Innovation, Invest

KetoSwiss launches first product in the USA

The Basel-based biotech startup KetoSwiss develops innovative therapies for neurological disorders. Following a successful capital increase, the company now has...

Read More
Basel Area treads unique path
Basel Area Business & Innovation, Innovation, Invest

Basel Area treads unique path

Basel Area is responsible for both location and innovation promotion. This approach, which is unique across Switzerland, is very successful...

Read More
Alentis secures 67 million US dollars
Basel Area Business & Innovation, Innovation, Invest

Alentis secures 67 million US dollars

The Basel-based biotechnology company Alentis Therapeutics has secured 67 million US dollars in a series B funding round. The funds...

Read More
RocketVax secures partners for coronavirus vaccine in Basel
Basel Area Business & Innovation, Innovation

RocketVax secures partners for coronavirus vaccine in Basel

RocketVax has found cooperation partners for the development of its innovative coronavirus vaccine. The University Hospital of Basel, the University...

Read More
1 2 3 15

Do you have a question? We'd like to hear from you.